1.53 USD
▼-0.05-3.16%
盘后 1.70 0.00%
2026-09-16
市值
$10.15M
市盈率
—
EPS
-3.72
股息率
—
52 周区间
0.97 – 14.85
成交量
43.99K
Beta
0.94
目标价
19.33
52W 低 0.9752W 高 14.85
价格走势
公司简介
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece...